Loading...
Market
Which company will be the biggest competitor to Galderma's Nemluvio® in the US by August 13, 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Market research reports and industry analysis
Story
Galderma Gains FDA Approval for Nemluvio® to Treat Prurigo Nodularis
Aug 13, 2024, 05:09 AM
Galderma, a Swiss pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for its drug Nemluvio® (nemolizumab). This medication is intended for adult patients suffering from Prurigo Nodularis, a chronic skin condition characterized by itchy nodules. The FDA approval marks a significant advancement for Galderma in the U.S. market, providing a new treatment option for patients with this challenging dermatological condition.
View original story
Similar markets
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
Amgen • 25%
Regeneron • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Novartis • 25%
Gilead Sciences • 25%
Bristol Myers Squibb • 25%
Other • 25%
Takeda • 25%
Amgen • 25%
Novo Nordisk • 25%
Other • 25%
Alopecia treatment • 25%
Psoriasis treatment • 25%
Eczema treatment • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%